Nichole Tucker

At Cleveland Clinic Lerner College of Medicine, a medical student set out to answer a question that is rooted in biology and inequity. Under the mentorship

For patients with multiple myeloma, emerging therapies are producing increasingly durable responses and raising expectations for longer progression-free su

Venous thromboembolism (VTE) remains a frequent early complication among patients with transplant-eligible, newly diagnosed multiple myeloma (TE-NDMM) despite contemporary treatment and routine thromboprophylaxis, according to new data from the phase 3 CASSIOPEIA trial presented at the 2026 International Society on Thrombosis and Haemostasis (ISTH) Congress. Investigators found that most events occurred within the first 6 months of treatment, highlighting the importance of timely thromboprophylaxis. 1

Rapid platelet gains, durable responses, and preserved COVID vaccine immunity position efgartigimod as a promising new option for ITP, ISTH 2026 data suggest.